Key Findings:  The authors concluded that preclinical results suggest that targeting the ECS for prevention and treatment of HIV-NP is a plausible therapeutic option. Furthermore, clinical evidence shows that inhaled cannabis alleviates HIV-NP. More specifically, 2-AG and AEA, WIN 55,212-2, β-caryophyllene, AM1710, JWH015, JWH133; FAAH inhibitors (palmitoylallylamide, URB597 and PF-3845) prevented the development of and/or attenuated established HIV-NP.
Type of Study:  Meta-analysis
Study Result:  Positive
Study Location(s):  Kuwait
Year of Pub:  2021
Cannabinoids Studied:  AM-x Synthetic Cannabinoids, JWH-x Synthetic Cannabinoids, HU-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Anandamide (AEA), 2-Arachidonoyl Glycerol (2-AG), Other Related Compounds
Phytocannabinoid Source:  Unspecified
Terpenes Studied:  ß-Caryophyllene